Related Experiment Videos
Management of community-acquired pneumonia in children
Krishne Chetty1, Anne H Thomson
1Department of Paediatrics, John Radcliffe Hospital, Headington, Oxford, UK.
Insights
Community-acquired pneumonia (CAP) in children is often viral but bacterial causes like Streptococcus pneumoniae are significant. Early diagnosis and appropriate antibiotic treatment, alongside vaccines like PCV-7, are crucial for managing this common childhood illness.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Community-acquired pneumonia (CAP) is a major global cause of illness and death in children.
- Viral infections are the most frequent cause in young children, while Streptococcus pneumoniae is the leading bacterial pathogen.
- Atypical organisms may be more prevalent than previously understood, presenting similarly across pediatric age groups.
Purpose of the Study:
- To review the etiology, diagnosis, treatment, complications, and prevention of community-acquired pneumonia in children.
- To highlight key clinical indicators for bacterial pneumonia and recommended therapeutic strategies.
- To discuss the impact of antibiotic resistance and the role of vaccination in CAP prevention.
Main Methods:
- Literature review of studies on pediatric community-acquired pneumonia.
- Analysis of etiological factors, clinical presentation, and diagnostic criteria.
- Evaluation of current treatment guidelines, including antibiotic choices and supportive care.
Main Results:
- Bacterial pneumonia should be suspected in febrile children with tachypnea and chest recession; oxygen saturation below 92% requires immediate therapy.
- Oral amoxicillin is effective for non-severe pneumonia, while parenteral antibiotics are used for severe cases.
- Increasing penicillin resistance in S. pneumoniae and macrolide resistance are concerns, necessitating careful antibiotic selection and consideration of combination therapy for atypical pathogens.
- Ultrasonography and intercostal drainage with fibrinolytic therapy improve outcomes for complications like empyema.
- The 7-valent pneumococcal conjugate vaccine (PCV-7) shows promise in reducing CAP incidence in early childhood.
Conclusions:
- Effective management of pediatric CAP involves prompt diagnosis, appropriate antibiotic selection considering local resistance patterns, and supportive care.
- Preventative strategies, particularly pneumococcal conjugate vaccination, are vital in reducing the burden of CAP in children.
- Further research into atypical pathogens and antibiotic stewardship is warranted to combat resistance and improve patient outcomes.
Abstract:
Community-acquired pneumonia (CAP) is a significant cause of childhood morbidity and mortality worldwide. Viral etiology is most common in young children and decreases with age. Streptococcus pneumoniae is the single most common bacterial cause across all age groups. Atypical organisms present similarly across all age groups and may be more common than previously recognized.A bacterial pneumonia should be considered in children presenting with fever >38.5 degrees C, tachypnea, and chest recession. Oxygen therapy is life saving and should be given when oxygen saturation is <92%. For non-severe pneumonia, oral amoxicillin is the antibacterial of choice with low failure rates reported. Severely ill children are traditionally treated with parenteral antibacterials. Penicillin non-susceptible S. pneumoniae prevalence rates are increasing and have been linked to community antibacterial prescribing. Most pneumococci remain sensitive to high-dose penicillin-based antibacterials but macrolide resistance is also a problem in some communities. However, primary combination treatment with macrolides is indicated in areas where there is a high prevalence of atypical organisms. The most common complications in CAP are parapneumonic effusions and empyema. The use of ultrasonography combined with intercostal drainage augmented with the use of fibrinolytic therapy has significantly reduced the morbidity associated with these complications. There is increasing evidence that a preventative strategy with the 7-valent pneumococcal conjugate vaccine (PCV-7) results in a significant fall in CAP in early childhood.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:14Atypical Pneumonia